Evonik industries licenses ERGO genomics platform for production of
specialty chemicals from microbial genomes
24 November 2008
Integrated Genomics, Inc has licensed the ERGO genomics platform for
use in research and production systems to Evonik Industries, a global
leader in specialty chemicals.
Under the terms of the agreement, scientists of the Evonik
Science-to-Business Center Biotechnology will use the ERGO system to
optimize their production strains and find new methods for high yield
production of specialty chemicals.
“We have found the ERGO discovery system to be an exceptionally
useful tool for our metabolic engineering projects and expect that it
will assist us in developing new production strains for higher and more
cost effective production of biological compounds,” said Dr Thomas Haas,
Director Science-to-Business Biotechnology Center at Evonik.
Optimised for analysis of microorganisms, ERGO integrates biological
data from genomics, biochemistry, gene expression studies, genetics and
literature. Reaching beyond conventional systems for functional analysis
by DNA sequence alone, Integrated Genomics' platform combines
pattern-based analyses with a repertoire of comparative genomics tools
for gene visualisation in the contexts of regulation, expression data,
phylogeny, chromosomal neighborhoods and gene fusions.
ERGO contains more than 1500 genomes at various stages of completion,
as well as the largest available collection of networked cellular
Bookmark this page